The Clorox Company (NYSE: CLX) — A Best-in-Class Franchise at Its Cheapest-Ever Multiple, Abandoned for the Sin of Not Growing

Independent fundamental research. Fiscal year ends June 30. Price and data as of 2026-06-27 (last close $97.54, 2026-06-26).

⚡ Claude’s Take

This block is the author’s own subjective opinion and general information only — not investment advice. The analytical body below takes no position and carries no price target; this block is the single, labeled exception.

Verdict: HOLD / accumulate-on-weakness. Not a short. A genuine quality-on-sale situation that still lacks a growth catalyst — own it for the ~5% yield, the best-in-class return, and the cheapest-ever multiple, not for a re-rating you can underwrite. Conviction: MEDIUM. Directional zone: fair value ~$100–120 on the ~$7 normalized EPS management itself endorses (≈14–17x, still a discount to the staples group); accumulate in the low-$80s–low-$90s where the dividend yield pushes toward 5.5%+ and you are buying near the decade low; don’t chase above ~$125; bear case low-$70s if the no-growth-plus-secular-decline narrative wins.

Here is the tension, stated plainly. Clorox earns a ~27% return on invested capital — at or above Colgate, P&G, Kimberly-Clark and Church & Dwight — yet trades at its cheapest valuation in a decade on every metric (composite own-history percentile ~3rd; trailing P/E 15.8x at the 4th percentile; ~11x trailing / ~9.5–10x forward EV/EBITDA, the cheapest of the entire staples cohort). The market is pricing CLX 6–8 P/E turns below a normal staple multiple, discounting roughly two points of perpetual growth versus peers, for a Dividend Aristocrat (47+ straight raises) yielding ~2x its own historical norm. The factor tape confirms it: this is a low-beta (0.25), low-vol, dividend-yield, value-loaded staple that has been abandoned, not crowded — negative Sharpe at every horizon out to ten years, a five-year falling knife that round-tripped from a ~$238 COVID blow-off to an $86 low last month. The same low-vol/dividend bid that lifted Colgate and P&G into 85th-percentile-rich multiples never rescued Clorox, because company-specific overhangs (the 2023 cyberattack, the 2025 ERP go-live, stagnant volumes) dominate. The single sharpest data point: an ex-Chevron-CFO director has made the only three open-market insider purchases in two years, averaging down from $137 to $86.

What keeps this a HOLD rather than a table-pounding BUY is that the bears are not wrong about the core defect — this is a no-growth business. Normalized organic growth is ~2–3%, the reported top line has been flat at $7.1–7.4B for five years, roughly half the mix (bleach, Glad bags, cat litter) is commodity-exposed and private-label-contested, Walmart is 27% of sales and rising, and the FY26 “recovery year” just proved margins can still reverse — management cut the full-year gross-margin guide from down ~100bps to down 250–300bps on an oil shock, ERP cost overruns and GOJO dilution. The framing is washed-out value, not compounder — the upside is a multiple re-rating toward the peer norm, and re-ratings need a catalyst (returning organic growth + clean post-ERP execution) that has not yet arrived. Flip-bullish trigger: two consecutive quarters of ≥3% organic growth with gross margin holding ≥45% and the ~$7 EPS base intact — that would convert “value trap” into “quality compounder re-rating.” Flip-bearish trigger: organic growth stalls toward zero with the value-consumer trading down to private label in bleach/litter/bags while oil-cost inflation re-compresses margin — “cheap” then stays cheap and the dividend coverage thins. Tag: an Aristocrat in the bargain bin — you’re paid 5% to wait for the growth, and the only insider buying agrees.

📈 Stock Price Action — Five-Year Event Map

Factual price history, not a recommendation. Price moves are FACT; attributed causes are INTERPRETATION. No price target, no support/resistance levels.

The arc. Clorox is a five-year falling knife that round-tripped from a pandemic blow-off to a decade-low and has only just stopped falling. The split/dividend-adjusted shares peaked at ~$197 in August 2020 (nominal close ~$238); they have made no net progress in five years and are down. The trailing-five-year high is ~$160 (December 2024); the recent low is $86.12 (5 May 2026), the lowest in a decade. At $97.54 the stock sits ~59% below the 2020 nominal peak, ~39% below the 5-year high, and just ~13% above last month’s trough. The 52-week range is ~$86–$131. Trailing returns are deeply negative at every horizon (1-year −13.6%, 5-year −7.7%/yr annualized), and the dividend yield (~5.1%) is roughly double its own historical norm — the textbook signature of an abandoned defensive-value staple.

Cycle narrative. (1–2) The pandemic turned Clorox’s core disinfecting franchise into a momentum stock and then punished it as demand normalized — a classic pull-forward round-trip. (3) The 2021–22 input-cost shock did the real damage: gross margin cratered roughly 1,000bps to 35.8%, exposing that Clorox’s pricing power, while real, is conditional, and the stock de-rated with the whole rate-sensitive staples complex. (4) A recovery rally on the margin-rebuild thesis was (5) interrupted by the August 2023 cyberattack, which halted order processing for weeks and cost durable share, especially in cat litter. (6) The market then rewarded two years of visible self-help margin recovery. (7) But from the December 2024 high the stock ground relentlessly lower as the realization set in that the franchise is structurally no-growth, compounded by the July 2025 ERP go-live, which whipsawed reported sales (retailers pre-built inventory, then destocked) and the FY26 margin guide. (8) The May 2026 low near $86 marked a decade trough; the modest bounce since reflects an oversold defensive name with a ~5% yield, not a thesis change. Each leg is cross-referenced to the earnings prints, the 8-K cyberattack disclosure (14 Aug 2023), and the ERP-transition commentary in the FY26 calls (Sections 6–8).

1. Executive Summary

The Clorox Company is a US-centric portfolio of category-leading household and personal-care brands — Clorox bleach and disinfecting wipes, Pine-Sol, Glad bags, Kingsford charcoal, Fresh Step litter, Hidden Valley Ranch, Brita, Burt’s Bees, and the CloroxPro professional franchise — generating ~$7.1B of annual sales across four segments (Health & Wellness, Household, Lifestyle, International). It is a high-return, slow-growth, capital-light branded manufacturer with a genuine but narrow and category-dependent moat.

The investment debate is unusually clean because the business quality and the valuation point in opposite directions. On quality: Clorox earns a ~27% normalized return on invested capital, holds #1 or #2 share in roughly 80% of its portfolio, recovered its gross margin a full ~950bps from the FY22 inflation trough (35.8%) back to pre-pandemic levels (45.2% in FY25), and has raised its dividend for 47+ consecutive years. On valuation: the stock trades at its cheapest level in a decade — composite own-history valuation percentile ~3rd, trailing P/E 15.8x (4th percentile), ~11x trailing EV/EBITDA (the cheapest of the staples cohort versus Colgate/P&G ~16x and Church & Dwight ~18x), and a ~5.1% dividend yield roughly double its own norm. Book equity is negative (~−$0.55/share), a buyback artifact rather than a distress signal.

The discount is not an earnings illusion — margins and ROIC have round-tripped to normal, so this is a multiple de-rating, not a depressed-denominator effect. What the market is penalizing is real: five years of flat reported revenue, ~2–3% structural organic growth, ~half the mix in commodity/private-label-exposed categories, 27% customer concentration in Walmart, and a string of idiosyncratic shocks (2023 cyberattack, 2025 ERP disruption, a 2026 oil-cost spike) that have repeatedly interrupted the recovery. Management’s own bridge to a ~$7 normalized EPS base — endorsed on the earnings calls — implies the stock trades at ~14x normalized earnings, well below where a franchise of this return profile historically sits.

Capital allocation is mixed: the long-term incentive plan is commendably built on economic-profit growth (a cost-of-capital metric), and the dividend was responsibly defended through the trough by zeroing buybacks — but the largest buyback in the window ($905M in FY21) was executed at the COVID-peak price, the program skipped the FY22–24 lows, and the April 2026 GOJO/PURELL acquisition (~$800M revenue, debt-funded, margin-dilutive) is a sizeable, unproven bet into a post-COVID-normalized category. Insider activity is mildly positive: the only open-market purchases in two years are three buys by one ex-CFO director, averaging down.

This memo takes no position and sets no price target. It frames the embedded expectations: at ~$97.54 the market underwrites permanent low-single-digit growth and “the margin recovery is as good as it gets,” for a high-ROIC Aristocrat at a generational-low multiple — quality on sale if growth returns, a value trap if it does not.

2. Business Overview

Clorox (founded 1913, headquartered in Oakland, California; ~7,400 employees; CEO and Chair Linda Rendle) manufactures and markets branded consumer and professional products, overwhelmingly in the United States. Revenue is consumable and habitual — low-ticket products bought on repeat — but explicitly non-contractual: the 10-K states the business “is based primarily upon individual sales orders” and the company “typically does not enter into long-term contracts with its customers.” Recurring demand is therefore a function of brand preference and shelf presence, not contracted backlog.

Segment structure (FY2025, net sales / segment-adjusted EBIT / EBIT margin):

Corporate & Other contributed only $38M of sales in FY25 (down from $221M in FY24 — that line had housed the vitamins/supplements business sold in September 2024) and a −$249M adjusted EBIT. Reconciling items between segment adjusted EBIT ($1,316M total-company) and GAAP pre-tax income ($1,078M) include net interest, a $118M divestiture loss, a +$70M net cyberattack insurance recovery, and a $111M digital-capabilities (ERP) investment charge.

By global product line (≥10% of consolidated sales): cleaning products 44%, bags & wraps 15%, food products 12%, cat litter 10%. This is the key structural fact about the portfolio — it is a collection of category-local US franchises, not a diversified global FMCG in the mold of P&G or Unilever. International is only 15% of sales and the lowest-margin segment. Health & Wellness is the crown jewel: 38% of sales at a 31% EBIT margin, anchored by the near-genericized Clorox trademark and the high-margin, sticky CloroxPro professional channel.

How it makes money. Clorox buys commodity inputs (resin, sodium hypochlorite, non-woven fabrics, soybean oil, corrugated, solvents, chemicals), converts them into branded packaged goods, spends ~11% of sales on advertising and sales promotion to sustain brand preference, and sells through mass retailers, club, grocery, dollar, drug, pet, home and e-commerce channels. Gross margin (~45% at peak) funds the brand reinvestment that is, in turn, the moat. The model is capital-light: capex runs ~$200–250M/year (~3% of sales), so operating profit converts to free cash flow at a high rate in normal years.

Verdict: A defensible, cash-generative, low-capital-intensity branded-consumables business — but one whose fortunes are concentrated in mature US categories and a single dominant customer (Walmart, Section 3). It is a quality business; whether it is a growth business is the entire question.

3. Industry Dynamics

The US household & personal-care (HPC) industry is mature, oligopolistic, high-barrier, supply-disciplined, and structurally slow-growing. Volume growth in normal years is low-single-digit; value growth ~2–4%. A handful of scaled multinationals (P&G, Colgate, Kimberly-Clark, Church & Dwight, Clorox, Unilever, Reckitt) compete with one another and with retailer private label. The pie barely grows; returns depend on share gains, premiumization/mix, productivity and capital return — not a rising tide.

The defining structural threat is private label. US private-label sales reached a record ~$282.8B in 2025 (~21.3% dollar / ~23.9% unit share) and have been growing roughly 3x faster than national brands. Crucially for Clorox, that threat is uneven across its portfolio: it bites hardest in the commodity-exposed categories that make up roughly half of Clorox’s mix — liquid bleach (chemically a commodity), trash bags (a resin commodity where store brands are an accepted substitute), and cat litter — and lightest in the differentiated franchises (Hidden Valley Ranch, Burt’s Bees, Brita). Clorox is therefore more private-label-exposed than premium-tilted peers such as Colgate. Management has repeatedly stated on recent calls that private label “did not increase” in aggregate through FY26 — a reassuring data point, but one to monitor category-by-category (bleach, Brita filters, wipes) rather than accept in aggregate.

Retailer power compounds it. The retail channel is a concentrated oligopoly — Walmart alone is 27% of Clorox’s sales, with Costco, Amazon, Kroger and the dollar channel behind it; the five largest customers approach half of consolidated sales. The 10-K explicitly flags that Walmart could “shift shelf space to private label,” “demand lower pricing,” and that “the use of the latest pricing technology by its customers may lead to category pricing pressures.” Clorox thus sits in the classic FMCG vise: retailers squeeze the branded profit pool from downstream while commodity suppliers squeeze from upstream. The FY22 margin collapse — gross margin from 45.6% to 35.8% in two years — was the textbook manifestation of that vise closing.

Capital-cycle read (Marathon lens). On the supply side this is the “good” side of the capital cycle: low asset growth, no flood of new capacity, incumbents returning cash rather than building, and high entry barriers (brand equity, shelf space, distribution scale, and — for disinfectants — EPA registration and efficacy-claim regulation). No new entrant is going to out-scale Clorox in US bleach or charcoal. But the structural offset is permanent: a flat demand pie plus a growing, disciplined, low-cost private-label competitor caps the incumbents’ pricing power and their ROIC ceiling. The 2021–23 input-inflation spike was a classic cost-cycle event that compressed returns industry-wide and has since normalized.

Verdict: structurally above-average, but not great. Defensive, high-barrier, cash-generative and supply-disciplined — but low-growth with a persistent private-label/retailer-power ceiling on returns. A good business in an OK industry. Clorox’s specific position within that industry is more commodity/private-label-exposed and more customer-concentrated than its premium peers, which is precisely what the valuation discount (Section 10) is paying for.

4. Competitive Position

Moat type: customer captivity via brand intangibles plus category-local economies of scale (regional/category, not enterprise-wide). Width: NARROW-to-moderate, and it varies sharply by category. This is not a wide enterprise moat.

Management claims roughly 80% of the portfolio holds #1 or #2 US market-share positions — a credible figure (treat the precise number as a hypothesis pending syndicated Circana/Nielsen verification), but one that obscures how different the franchises are. Applying the Greenwald taxonomy category by category:

Genuinely defensible (real pricing power, weak private-label substitution):

• Hidden Valley Ranch — the dominant #1 US ranch dressing, a near-genericized flavor brand in a taste-driven category where private label is a weak substitute. Real pricing power.
• Brita — a razor/razor-blade model (the pitcher installed base drives recurring filter sales) that creates a genuine switching cost on top of #1 share. The closest thing to a structural switching-cost moat in the portfolio.
• Burt’s Bees — premium natural personal care with ingredient/emotional positioning and broad channel distribution, differentiated against store brands.
• Kingsford — the dominant US charcoal brand (historically ~70%+ share), a scale-based cost advantage in a niche with seasonal brand loyalty.
• CloroxPro / Clorox Healthcare — institutional B2B disinfecting with EPA-registered efficacy claims embedded in healthcare and facility protocols, which create real switching costs and regulatory barriers. High-margin and sticky.

More contested (commodity-exposed; private label and retailer power bite hardest):

• Clorox bleach — the trademark is so strong it is nearly generic (“Clorox” means bleach), a powerful brand asset; but liquid sodium-hypochlorite bleach is chemically a commodity and private-label bleach is a credible cheap substitute. The brand premium is real but capped; the franchise defends share better than it defends price.
• Glad (bags & wraps, 15% of sales) — strong #1/#2 share, but trash bags are a resin-commodity category with heavy, accepted private-label penetration. Pricing power is thin and margins are resin-cost-sensitive; management has at times taken price down (e.g., the Glad 80-count bag) to defend share.
• Fresh Step / Scoop Away (cat litter, 10% of sales) — branded but increasingly commoditized against strong value and private-label competition; Clorox lost litter share after the 2023 cyberattack and is in a multi-year reinvention of the franchise.

The financial proof — and the single most revealing stress test. Clorox’s return on invested capital sat at ~27–29% for years (FY16 28.1%, FY18 29.5%, FY19–20 ~27%, FY21 25.1%) — unambiguous evidence of a durable advantage earning far above an ~7–8% cost of capital. Then the inflation shock hit, and ROIC collapsed to ~15% (FY22 14.7%, FY23 15.3%, FY24 15.5%) as gross margin fell ~1,000bps to 35.8%. It then fully recovered to 26.7% in FY25 as gross margin rebuilt to 45.2%. That round-trip is the moat’s MRI: a wide, unconditional-pricing-power franchise would not have seen margin crater that hard, because it could have re-priced inputs through. Clorox could not re-price fast enough — partly because its commodity-exposed categories face private-label discipline and partly because Walmart and other retailers resist increases. The full recovery proves the brand equity is durable; the depth of the trough proves the pricing power is conditional, not unconditional. Verdict: a real but NARROW moat — a collection of strong category-local franchises, several genuinely defensible (Hidden Valley Ranch, Brita, Burt’s Bees, CloroxPro, Kingsford) and several commodity-exposed and contested (bleach, Glad, litter). Enterprise-wide, the moat is narrow.

A measurement caveat that matters for the whole memo: Clorox’s reported ROE (171% in FY25, 51% in FY24) is not a moat signal — it is a thin-equity artifact, because total stockholders’ equity is only ~$482M after decades of buybacks (and is negative on a tangible/per-share basis). Throughout this memo, ROIC (~27% normalized) is the true return metric; ROE is meaningless here.

5. Growth History and Forward Opportunities

The headline is five years of going nowhere — on the surface. Reported net sales: FY20 $6,721M, FY21 $7,341M (+9.2%, the COVID disinfecting spike), FY22 $7,107M (−3.2%), FY23 $7,389M (+4.0%), FY24 $7,093M (−4.0%), FY25 $7,104M (+0.2%). Five years inside a $7.1–7.4B band, with no net progress.

But the flat reported line masks two offsetting forces: positive organic growth and deliberate portfolio shrinkage. FY25 organic sales (ex-FX, ex-divestitures) grew +5% — Health & Wellness +9%, Household +3%, Lifestyle +2%, International +5% — while reported sales were flat because divestitures (the vitamins/Better Health business sold September 2024; the Argentina business sold in FY24) subtracted roughly five points and FX subtracted more. The pruning was value-accretive (it raised portfolio mix and margin) but it shrank the top line, which is why the reported number understates underlying health.

The quality of that +5%, however, is lower than it looks, for two reasons. First, FY25 was lapping the August 2023 cyberattack, which had artificially depressed the FY24 base (FY24 Q1 sales were only $1,386M with collapsed margins), flattering every FY25 comparison. Second, the July 2025 ERP go-live pulled shipments forward into FY25 (Health & Wellness volume +11%, much of it channel pre-build), a one-time benefit that promptly reversed — FY26 Q1 sales fell to $1,429M (from $1,762M a year earlier) at an 8.4% operating margin. Strip out the cyberattack lap and the ERP pull-forward and normalized organic growth is ~2–3% low-single-digit, and FY25’s growth was volume-led with price/mix a headwind (the post-inflation pricing wave reversing into promotion). That is healthier than price-led growth in that it reflects real consumption, but it is structurally slow.

Forward opportunities (FY26 and beyond), in descending order of quality:

• CloroxPro / professional cleaning and disinfecting — the highest-quality vector: B2B, sticky, regulatory barriers, durable post-COVID hygiene awareness. The April 2026 GOJO/PURELL acquisition (Section 7) doubles down here.
• International margin recovery — a cleaner, higher-margin remaining footprint after the Argentina exit.
• Innovation and premiumization in the differentiated brands — Burt’s Bees, Brita refills, Hidden Valley line extensions, and the new “Clorox PURE” allergen-platform cleaning launch (running ahead of expectations per the FY26 calls).
• ERP/IGNITE productivity — the new digital backbone is intended to enable supply-chain agility and cost savings through FY26+ (the same project that caused the FY26 disruption).
• E-commerce/digital — a growth channel that is simultaneously a private-label and price-transparency risk.

Verdict: low-to-moderate quality growth. The reported five-year flatline overstates weakness (it is masked by deliberate divestitures), and underlying FY25 organic +5% looks good — but it is heavily flattered by one-time cyberattack-lapping and ERP pull-forward. Normalized organic growth is ~2–3%: defensive and durable, but structurally slow. This is a margin-recovery-plus-capital-return EPS story, not a revenue-growth story — which is exactly why the market refuses to pay a growth multiple.

6. Financial Quality

Margin trajectory — the central financial fact. Gross margin: 43.7% (FY18), 45.6% (FY20 COVID peak), 43.6% (FY21), 35.8% (FY22 inflation trough), 39.4% (FY23), 43.0% (FY24), 45.2% (FY25), 43.8% (trailing twelve months through Q3 FY26). Operating margin tracked the same V: 16.7% (FY21) → 10.1% (FY22) → 16.6% (FY25). EBITDA margin: 21.1% (FY18) → 13.3% (FY22) → 19.7% (FY25) → 19.0% (TTM). The recovery is largely done and round-tripped to pre-pandemic norms, driven by Clorox’s “holistic margin management” toolbox plus the four price increases taken during 2021–22. This is why the valuation discount is a multiple de-rating, not a depressed-earnings artifact — the earnings have already normalized.

Earnings and the quality-of-earnings flags. GAAP net income swung violently through the cycle as impairments and one-offs moved through: FY21 $710M, FY22 $462M, FY23 $149M (hit by a $445M asset impairment), FY24 $280M (depressed base), FY25 ~$810–824M (diluted EPS ~$6.5). The trailing-twelve-month figure (through Q3 FY26) is net income $756M, diluted EPS $6.17 — the denominator on the 15.8x trailing P/E. Several items distort the run-rate and must be normalized before drawing valuation conclusions:

• ERP shipment timing: inflated FY25 sales ~3.5–4% and will depress FY26 sales ~7.5 points; the cleanest read is management’s own bridge to a ~$7 normalized EPS base (FY26 reported plus a ~$0.90 ERP add-back, explicitly confirmed by the CFO on the Q4 FY25 and Q1 FY26 calls).
• Cyberattack lapping flattered FY25 comparisons against a depressed FY24.
• One-offs in FY25: a $118M divestiture loss, a +$70M net cyber insurance recovery, and a $111M digital-capabilities charge.

Cash flow and the dividend-coverage tension. Operating cash flow: FY21 $1,276M, FY22 $786M, FY23 $1,158M, FY24 $695M, FY25 $981M, against capex of ~$200–250M. The critical observation is dividend coverage through the cycle:

• FY24 trough: OCF $695M − capex ~$192M = FCF ~$503M < dividends $595M — the dividend was not covered by free cash flow, and on a GAAP basis (net income $280M) the payout ratio exceeded 100%. The 47-year raise streak was defended out of the balance sheet, not out of current cash flow.
• FY25 recovery: OCF $981M, FCF ~$760–780M vs. dividends $602M — comfortably covered at ~1.25–1.3x, GAAP payout ~73%.

So the dividend is now re-covered with cushion on normalized earnings, but coverage is thin by staples standards and remains cyclically exposed — which is part of why the ~5% yield reflects market skepticism rather than generosity.

Balance sheet — investment-grade, but optically alarming. Net debt ~$2.3B against total debt ~$2.88B (roughly 1.5–1.8x EBITDA) — moderate leverage. Book equity is negative on a per-share basis (~−$0.55/share; tangible book is more deeply negative, ~−$11/share). This is not distress — it is the cumulative arithmetic of decades of buybacks and special distributions exceeding retained earnings, on top of intangible write-downs. Clorox is investment-grade and free-cash-flow-positive. But the negative equity (a) makes book-based ratios (ROE, P/B) meaningless, (b) leaves little margin for error if a bad year coincides with the dividend commitment, and © screens poorly for quantitative/quality-factor buyers — a structural reason the stock is under-owned. The April 2026 GOJO acquisition and the resumed buyback add incremental leverage (a new $1.0B 364-day revolver was put in place to fund GOJO).

Verdict: do economics improve with scale? Yes — they already did, and they have recovered. The franchise demonstrably earns a ~27% ROIC and ~45% gross margin at scale; the FY22 trough was a cost-cycle event, not a structural break, and it has reversed. The quality concerns are not about the level of returns (which are excellent) but about the durability of the recovery (the FY26 margin guide cut shows it is not yet structurally locked), the thin dividend coverage in a bad year, and the negative-equity optics.

7. Capital Allocation

Verdict: mixed — adequate-to-good on philosophy and incentive design, poor on buyback execution, and unproven on the most recent large bet.

The incentive design is a genuine positive. The long-term incentive plan (60% performance shares / 40% restricted shares) is measured on economic-profit growth over three years — a capital-charge, value-based metric that penalizes growth which fails to beat the cost of capital. That is materially better than the EPS- or revenue-only metrics common in the sector, and Clorox discloses economic profit in its pay-versus-performance table. The annual incentive is on net sales (50%), net earnings (30%) and gross margin (20%). The presence of a cost-of-capital metric in the long-term plan is a real alignment signal — it is the single best argument that management thinks about value creation, not just size.

The buyback record is the weak spot. Over the cycle Clorox bought high and skipped the lows. The largest repurchase in the window — $905M in FY21 — was executed at the COVID-demand peak when the stock traded ~$180–220, near its all-time high; it has been value-destructive in hindsight. The program was then suspended (~$0 in FY22–24) precisely when the stock fell to $120–140 and repurchases would have been most accretive — understandable given trough free cash flow and the priority on defending the dividend, but it means Clorox did not buy low. Buybacks resumed modestly in FY25 (~$332M at ~$120–150), better timed but small. Net share count is roughly flat post-FY21 (~123M), with buybacks merely offsetting ~$50–80M/year of stock-based compensation. This is a recurring staples failing — pro-cyclical, peak-multiple repurchasing — and it is the clearest evidence that management is a competent custodian rather than an opportunistic allocator.

Portfolio moves — prudent pruning plus one sizeable bet. The recent divestitures were sensible and value-accretive: exiting FX-volatile Argentina (FY24) and the vitamins/Better Health business (September 2024) — the latter an explicit admission that the prior vitamins acquisitions “did not contribute what we had anticipated,” i.e., a failed deal corrected. Buying out the 20% Glad JV minority from P&G (~January 2026) was a cheap, sensible control gain (+~20–25bps gross margin). GOJO/PURELL (closed 1 April 2026) is the largest deal in years: ~$800M of revenue, ~80% B2B hand hygiene, financed with cash and new debt, EBITDA-margin in line with Clorox but gross-margin-dilutive (B2B mix), with ~$50M of targeted run-rate synergies by years 2–3 and ~$110M of incremental FY27 interest expense. The strategic fit is good — it extends the Health & Wellness/professional franchise where Clorox has a credible track record — but the returns are unproven and it is a bet into a category (sanitizer) that boomed in COVID and has since normalized. Marathon-style caution is warranted: watch the integration and whether the (undisclosed) price clears the cost of capital.

Reinvestment intensity. Advertising and sales promotion is held at ~11% of sales — among the higher ratios in staples, consistent with a brand-equity moat thesis (management claims “industry-leading advertising ROI,” an unverified hypothesis). This is the right place to spend, and the consistency through the trough is a positive.

Governance. Linda Rendle holds the combined Chair/CEO role (since January 2024) — a mild governance negative, partially offset by a lead independent director. No founder or dual-class control issue; the largest holders are index funds. The June 2026 appointment of Chris Hyder as the company’s first dedicated COO signals a focus on operational execution post-ERP and plausibly succession planning.

Net: Not a serial capital mis-allocator, but not a standout steward either. The comp metrics are better than the buyback record; the dividend was responsibly protected; the pruning was smart; GOJO is the open question. Adequate, leaning good — with the buyback execution the clearest blemish.

8. Changes and Headwinds — Last Two Years

1. Cyberattack (August 2023). Unauthorized activity on IT systems forced Clorox to take systems offline, disrupting order processing and shipments for weeks. It drove durable FY24 share losses (especially in cat litter, where owners switched litter and many did not return) and inflated the FY24 cost base with recovery spend, creating a lapping tailwind in FY25. Largely resolved, but it left a share-recovery overhang and demonstrated the company’s idiosyncratic operational fragility.

2. ERP / “streamlined operating model” go-live (July 2025, the start of FY26). A greenfield replacement of a 25-year-old ERP system. It caused (a) a FY25 Q4 retailer pre-build of ~2 weeks of inventory (+3.5–4% to FY25 sales) ahead of a brief order blackout, then (b) a FY26 Q1 destock (−14–15% reported Q1 sales; a ~7.5-point headwind to FY26), plus out-of-stocks and lost share in August 2025 and higher-than-planned stabilization costs (logistics, expediting, labor) and delayed cost savings that forced the H2 FY26 gross-margin guide cut. Declared complete in Q3 FY26. This is the dominant source of FY25–26 optical volatility — and, prospectively, a cleaner digital backbone and potential productivity source.

3. Portfolio reshaping. Divested Argentina (FY24) and the vitamins/Better Health business (September 2024); bought in the Glad JV minority (~January 2026). Net positive for mix and margin.

4. GOJO/PURELL acquisition (closed 1 April 2026). ~$800M B2B hand-hygiene revenue; debt-funded; gross-margin-dilutive near-term (~50bps ongoing plus a one-time ~150bps Q4 inventory step-up); integration risk; a post-COVID-normalized category. Strategic fit good, returns unproven.

5. The FY26 guidance degradation. The “recovery year” became a “kitchen-sink-plus-macro-shock” year. The original Q4 FY25 framework (ex-ERP) was organic −1% to +2%, gross margin flat to +50bps, adjusted EPS +2–4%. By Q3 FY26 management cut the full-year gross-margin outlook from down ~100bps to down 250–300bps, on higher supply-chain costs, deliberately delayed cost savings (deprioritized to stabilize the ERP), GOJO dilution, and — newly — a Middle East oil shock (~$100/bbl ≈ $20–25M / ~130bps Q4 gross-margin hit) with unquantified FY27 annualization risk. EPS pressure of ~$0.40 at the midpoint, “the majority related to cost pressures.” This is the single most important recent development for the bear case: it proves the margin recovery is not yet structurally locked.

6. Leadership and macro. Chris Hyder named first COO (June 2026); Rendle remains combined Chair/CEO; Luc Bellet is CFO. Tariffs are a ~$40M FY26 headwind (USMCA exemptions assumed). GLP-1 weight-loss drugs are a watch item for the Hidden Valley/food category (down mid-single-digit). No material litigation flagged.

Verdict: net neutral-to-modestly-constructive, but with real and partly new offsets. The cyberattack and ERP disruptions are largely behind the company (one-time, now a clean backbone), and the pruning was value-accretive. But GOJO dilution/integration, an oil-cost shock that could bleed into FY27, still-thin dividend coverage, and weak cat-litter/food categories are live. The “recovery is done” narrative the bulls want is not yet fully earned — H2 FY26 proved the margin can still reverse.

9. Risk Analysis

Catastrophic-loss / total-loss assessment: Very low. Clorox is an investment-grade, free-cash-flow-positive, ~$12B market-cap franchise with #1/#2 share in most categories and a 47-year dividend record. The realistic downside is a value trap — years of “cheap stays cheap” with a ~5% yield as the only return — not impairment of capital. The negative book equity is an accounting artifact, not a solvency signal.

10. Valuation Discussion (Embedded Expectations)

The central fact: Clorox trades at its cheapest valuation in a decade on essentially every metric. On its own multi-year history (AZI valuation index), the composite valuation percentile is ~3rd, the trailing P/E (15.8x) is the 4th percentile, and the price/sales (1.77x) is the 1.85th percentile. Price/book is null because book equity is negative. At ~$97.54, market capitalization is ~$11.8B; with ~$2.3B net debt, enterprise value is ~$14.1B (note: ROIC’s reported FY2025 EV field of $2.87B is a data error — the market-cap component is missing — and must be discarded).

Multiples at $97.54:

• Trailing P/E 15.8x (on TTM diluted EPS $6.17); forward P/E ~13.7x on the ~$7.10 normalized/forward base.
• EV/EBITDA ~11.0x trailing / ~9.5–10x forward — versus a normalized historical range of ~15–21x and a current staples-peer range of ~14–18x.
• EV/sales ~2.1x (vs. own history ~3–4x).
• Dividend yield ~5.1% ($4.96/year) — roughly 2x Clorox’s own historical ~2.5–3.0% norm.

Peer comparison — Clorox is the cheapest of the cohort on every line:

Clorox and Kimberly-Clark are the two “cheap, abandoned, high-yield” staples; Colgate, P&G and Church & Dwight are the “expensive, crowded, low-vol-bid” staples (CL and PG sit at the 85th and 89th own-history valuation percentiles). But Clorox earns a much higher ROIC (~27%) than KMB (~18.6%) or CHD (~13%), so on a quality-adjusted basis it is arguably the cheapest-versus-quality name in the entire group. The discount is a de-rating story — category/secular doubt, customer concentration, the cyber/ERP overhang, and negative-equity optics — not a returns-quality story.

Embedded-expectations analysis. Running a reverse-Gordon calculation (payout ~70%, low-beta cost of equity ~7.5–8.0%): at today’s ~13.7x forward P/E, the market is pricing in only ~2.4–2.9% perpetual growth. A “normal” quality-staple multiple of 20–22x would imply ~4.0–4.8% perpetual growth. The gap is 6–8 P/E turns — the market is discounting roughly 1.5–2.0 points of perpetual growth versus where it prices Clorox’s peers, for a business whose normalized EPS algorithm is mid-single-digit and whose gross margin has fully recovered. In plain terms: at $97.54 you are paying ~14x for the ~$7 normalized EPS management itself bridges to, with a ~5% yield, for a 27%-ROIC Aristocrat. The market is underwriting permanent low-single-digit growth, “the margin recovery is as good as it gets,” and a structural discount for the negative book and customer concentration.

Scenario analysis (illustrative; explicit assumptions; not a price target):

• Bear (~low-$70s): organic growth ~0–1%; gross margin slips to ~42–43% on input re-inflation and value-consumer trade-down; adjusted EPS stalls ~$6.50–6.75; the multiple de-rates further to ~11–12x P/E / ~9x EV/EBITDA as a terminal-decline narrative (charcoal/bleach) takes hold. Driver: the value trap is real.
• Base (~$100–115): organic growth ~2–3%; gross margin holds ~44–45%; FY26 adjusted EPS ~$7.10 growing ~4–6%/year; the multiple re-rates modestly toward — not to — the staple norm (~14–15x P/E / ~10–11x EV/EBITDA). Spot already roughly equals a no-re-rating base; modest re-rating delivers low-teens upside plus the ~5% yield.
• Bull (~$135–160): organic re-accelerates to ~3–4% on innovation, the digital/productivity program and international; gross margin pushes ~46%+; adjusted EPS ~$7.50–8.00 by FY27–28; the multiple re-rates toward the staple norm (~18–20x P/E / ~13–14x EV/EBITDA) as the market re-accepts Clorox as a quality compounder. The re-rating, not the earnings, is the bull case.

The asymmetry is the inverse of the premium staples. Where Colgate, P&G and Church & Dwight trade as overpaying-for-safety names at 85–89th-percentile multiples, Clorox is the cheapest-ever own-history name in the group. The risk here is a value trap (legacy-category decline plus no catalyst), not a crowded-trade unwind. No price target; no recommendation — the valuation is presented as embedded expectations and scenarios only.

11. Variant Perception

Consensus view: Clorox is a structurally no-growth, cyclically-and-operationally-accident-prone household-products company whose best days (the COVID disinfecting boom) are behind it; the margin recovery is done, organic growth is stuck at ~2%, half the portfolio is commodity/private-label-exposed, and a 27% Walmart concentration caps pricing — so a perpetual discount to higher-growth, premium-mix peers is deserved. The tape agrees: five years of negative risk-adjusted returns, a multi-year falling knife, sell-side ambivalence.

The factor evidence sharpens this. FactorsToday reads Clorox as a classic defensive low-beta (0.25), low-vol, dividend-yield staple with a positive Value loading (+0.17) and a negative OilPrice (input-cost) loading — and a deeply negative track record: negative Sharpe at every horizon out to ten years (5-year −7.7%/year, 1-year −13.6%), a −56% lifetime max drawdown, relative strength ~50% below its peak. Critically, ~23%/year of idiosyncratic volatility and an R² of only ~0.33 to the factor model mean most of Clorox’s risk and return is company-specific (cyberattack, ERP, category), not market beta. It shares Colgate’s and P&G’s defensive DNA but had the opposite price outcome: the low-vol/dividend bid that lifted those names into rich multiples never rescued Clorox, because stock-specific overhangs dominated. The factor tape says “abandoned defensive value,” not “crowded trade.”

Strongest bull case (the variant): This is a washed-out, high-quality franchise priced for permanent stagnation that is unlikely to be permanent. The business earns a ~27% ROIC, recovered its gross margin a full ~950bps, holds #1/#2 share across the portfolio, and yields ~5% (2x its norm) as a 47-year Aristocrat. Management itself bridges to a ~$7 normalized EPS — so the stock trades at ~14x normalized earnings, a generational-low multiple, while the most informed insider (an ex-Chevron CFO director) is the only open-market buyer, averaging down from $137 to $86. If organic growth merely returns to ~3% and post-ERP execution is clean, the multiple re-rates toward the peer norm and you make the re-rating plus the dividend. Consensus is offsides-negative on a quality Aristocrat at its cheapest-ever price.

Strongest bear case (the variant): It is a genuine value trap. The categories that anchor the moat (charcoal, bleach) face slow secular and format decline; growth is structurally ~2% and partly price-led; the H2 FY26 margin cut proved the recovery can reverse on the next oil shock; the GOJO bet is a margin-dilutive, debt-funded reach into a normalized category; the negative book equity and 27% Walmart concentration justify a permanent discount; and five years of negative Sharpe are not noise — they are the market correctly pricing a no-growth business. “Cheap” stays cheap because there is no catalyst, and you collect a 5% yield while the multiple does nothing for another five years.

The 3–5 assumptions that decide it: (1) Does normalized organic growth hold ~2–3% (base) or fade toward 0–1% (bear)? (2) Is the ~45% gross margin structural, or does the next input-cost cycle re-compress it? (3) Does private label finally make inroads in bleach/Glad/litter, or does Clorox’s brand equity hold the line? (4) Does GOJO earn its cost of capital? (5) Does the market ever re-rate a no-growth Aristocrat, or is the discount permanent? Falsification: the bull case breaks if two consecutive quarters show organic growth fading toward zero with margin re-compressing; the bear case breaks if Clorox strings together ≥3% organic growth with a stable ~45%+ margin and the ~$7 EPS base holds, forcing the re-rating.

12. Fact vs. Interpretation

13. Open Questions

1. Is the ~45% gross margin structural or cyclical? The H2 FY26 cut to −250/−300bps on an oil shock suggests it is not yet locked. What does a normalized FY27 gross margin look like once GOJO dilution, the oil annualization and the resumed cost-savings program net out?
2. What is the true normalized organic growth rate once cyberattack-lapping and ERP pull-forward fully wash out — 2%, 3%, or something below?
3. Will GOJO/PURELL earn its cost of capital? The price is undisclosed; the ~$110M FY27 interest implies a mid-single-digit-billion enterprise value against ~$800M of revenue — what EBITDA and synergy path justify it?
4. Can the ~80% #1/#2 share claim be verified against syndicated Circana/Nielsen data, and how stable is share specifically in the contested categories (bleach, Glad, litter)?
5. Does private label finally break through in Clorox’s commodity-exposed half of the portfolio if the value-consumer environment persists, or does the brand hold?
6. Is the combined Chair/CEO structure and the new COO appointment a prelude to a CEO succession, and does that introduce strategic-continuity risk?
7. What is the FY27 annualized oil/input-cost exposure that management declined to quantify on the Q3 FY26 call?

14. What Must Be True

For the bull case (a re-rating toward the staple norm) to be right:

• Normalized organic growth must hold at ~2–3% and ideally re-accelerate toward ~3–4% — proving the business is slow-growing, not declining.
• Gross margin must stay ~45%+ structurally through the next input-cost cycle, with the FY26 cut proving a one-off (oil + ERP) rather than a pattern.
• Private label must not break through in bleach/Glad/litter; brand equity holds share.
• The ~$7 normalized EPS base must prove real and grow mid-single-digit, with GOJO additive rather than dilutive to value by FY28.
• Falsification test: two consecutive quarters of organic growth fading toward 0–1% with gross margin re-compressing below ~43% would break the bull case — it would confirm structural stagnation and justify the discount.

For the bear case (a permanent value trap) to be right:

• Organic growth must fade toward 0–1% as legacy categories (charcoal, bleach) decline secularly and the value-consumer trades down.
• The ~45% gross margin must prove cyclical, re-compressing on the next oil/resin cycle.
• The multiple must stay at ~11–14x indefinitely with no catalyst, so the only return is the ~5% yield.
• Falsification test: three-plus consecutive quarters of ≥3% organic growth with a stable ~45%+ gross margin and the ~$7 EPS base intact would break the bear case — it would force a re-rating toward the peer norm and convert “value trap” into “quality compounder on sale.”

The two cases share a single fulcrum: does organic growth return, or doesn’t it? Everything else — margin durability, the multiple, the dividend cushion — flows from that one variable. At ~$97.54 the market has bet, with conviction, that it does not. The ~5% yield, the 27% ROIC, the cheapest-ever multiple, and the lone insider buyer averaging down are the evidence that the bet may be too pessimistic.

15. Source Appendix

See the separate Source Appendix (Appendix B in the combined report) for the full, dated citation list. Primary sources include: Clorox FY2021–FY2025 Forms 10-K (EDGAR CIK 0000021076), the FY2025 10-K and Ex-99.1 financial statements (filed 2025-08-08); the DEF 14A proxy (filed 2025-10-07); the Form 4 corpus (145 filings since July 2024); 8-K material-event filings (cyberattack 2023-08-14, VMS divestiture 2024-09-10, GOJO agreement/revolver 2026-03-10, COO appointment 2026-06-17); the FY2026 Q1–Q3 and FY2025 Q4 earnings-call transcripts (ROIC.ai); ROIC.ai fundamentals and ratios; AZI valuation-index own-history percentiles and price history; and FactorsToday factor/leaderboard data. Public peer disclosures (Colgate, P&G, Kimberly-Clark, Church & Dwight, Unilever) inform the industry-structure and peer-multiple comparisons.

This analysis carries no investment recommendation and no price target. The only position expressed anywhere in this article is in the clearly-labeled “Claude’s Take” block at the top, which is the author’s own subjective opinion and general information only — not investment advice. Do your own research.

APPENDIX A — Standard Diligence Questionnaire

The Clorox Company (NYSE: CLX) — supplemental diligence. FY ends June 30. Data as of 2026-06-27.

Labels: F = Fact, I = Interpretation, A = Assumption.

General

What thoughtful questions have other investors asked about this company? The recurring institutional questions: (1) Is the gross-margin recovery to ~45% structural or will the next input-cost cycle re-compress it (the H2 FY26 cut to −250/−300bps is exhibit A for the skeptics)? (2) Can Clorox grow organically above ~2% in mature, private-label-pressured categories? (3) Why is a 27%-ROIC Aristocrat trading at its cheapest-ever multiple — is it a value trap or quality on sale? (4) Was the GOJO/PURELL deal a smart extension or a margin-dilutive reach into a normalized category? (5) How worried should we be about the negative book equity and 27% Walmart concentration? (6) Is the dividend safe in a trough year given coverage exceeded 100% of FCF in FY24? (I)

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Roughly normalized, not extreme. Gross margin (45.2% FY25) and ROIC (~27%) have round-tripped to pre-COVID norms after the FY22 trough (35.8% / ~15%). FY26 is depressed by the ERP destock (~7.5pt headwind) and one-off oil/integration costs — the cleaner read is management’s ~$7 normalized EPS base. So reported FY26 understates; underlying is mid-cycle. (F/I)

Driven by the external environment or internal actions? Both. The margin recovery was internally driven (pricing + holistic margin management + cost savings); the FY22 collapse and the FY26 oil hit are external (input inflation); the cyberattack and ERP disruption were idiosyncratic/internal-execution events. (I)

How stable are revenues? Very stable in aggregate ($7.1–7.4B for five years) — consumable, habitual, non-discretionary demand — but stable means flat, not growing. (F)

Outlook for products/services; how big is the market — growing, shrinking, domestic or international? Mature US household & personal care; the category grows ~0–2% volume / ~2–4% value. ~85% domestic. Some categories face slow secular pressure (charcoal/grilling trends, cleaning-format shifts); CloroxPro/professional and natural (Burt’s Bees) are the better-growth pockets. The pie is essentially flat. (F/I)

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Modestly more — private label is at a record ~21% dollar share and growing ~3x national brands; retailer power (Walmart 27% of CLX sales) is rising. Brand incumbents remain entrenched, but the return ceiling is under structural pressure. (F/I)

How profitable is the business (ROIC, ROE)? Excellent on ROIC: ~27% normalized (15% trough FY22–24). ROE is meaningless (171% FY25) because book equity is negative/thin from buybacks — do not use it; use ROIC. (F)

How profitable is the industry — how many competitors, what barriers to entry? Above-average, oligopolistic (P&G, Colgate, Kimberly-Clark, Church & Dwight, Unilever, Reckitt + private label). Barriers are real: brand equity, shelf space, distribution scale, and EPA registration/efficacy regulation for disinfectants. (F/I)

Can the business be easily understood? Yes — branded household consumables, simple unit economics. (F)

Can it be undermined by foreign low-cost labor? Low risk — bulky, low-value-density, US-manufactured/US-sold goods with high freight-to-value; the real low-cost threat is domestic private label, not offshore labor. (I)

Do brands matter? What is the nature of competition? Brands matter unevenly. They confer real pricing power in Hidden Valley Ranch, Brita (razor/blade switching cost), Burt’s Bees, CloroxPro and Kingsford; they confer thinner pricing power in bleach, Glad bags and litter, where private label is an accepted substitute. Competition is brand vs. brand and brand vs. store-brand, mediated by powerful retailers. (I)

Customers’ switching costs? Low for the consumer in commoditized categories (bleach, bags, litter); higher in Brita (installed pitcher base → recurring filters) and CloroxPro (protocol/regulatory embedding). (I)

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Yes — the core brands (Clorox, Hidden Valley, Kingsford, Brita, Burt’s Bees) are worth far more than the ~$566M of carried trademarks/intangibles + $1,229M goodwill; decades of advertising have built off-balance-sheet brand equity. (I)

Off-balance-sheet liabilities? Operating leases (~$0.4B capitalized), standard purchase commitments, pension (modest). Nothing unusual flagged. (F)

How conservative is the accounting? Reasonable. The cycle saw large but disclosed impairments (FY23 $445M, FY21 $329M) and clearly-labeled one-offs (divestiture loss, cyber insurance recovery, ERP charge). The EP-based comp disclosure is a transparency positive. (I)

How CapEx-hungry is the business? Light — capex ~$200–250M/year (~3% of sales). High FCF conversion in normal years. (F)

Capital Allocation & Management

How much FCF, how is it used, what is the philosophy? FCF ~$760–780M (FY25 normalized); priority order is (1) dividend (sacrosanct, 47-year raise streak), (2) reinvestment/M&A, (3) buybacks (residual). Defended the dividend through the trough by zeroing buybacks FY22–24. (F/I)

Significant acquisitions recently? GOJO/PURELL (~$800M revenue, closed 1 April 2026, debt-funded, GM-dilutive) — the largest in years. Bought in the 20% Glad JV minority (~Jan 2026). Divested Argentina (FY24) and the vitamins/Better Health business (Sept 2024 — a conceded failed prior acquisition). (F)

Buying back shares? Yes, but poorly timed — $905M at the FY21 COVID peak (~$180–220), skipped the FY22–24 lows, resumed ~$332M in FY25 at ~$120–150. Share count roughly flat post-FY21; buybacks mostly offset SBC. (F/I)

Issuing large amounts of new shares to insiders? No — SBC is ~$50–80M/year (~1% of cap), routine. (F)

Compensation policy / incentive alignment? A genuine positive: long-term PSUs measured on economic-profit growth (cost-of-capital metric); annual plan on net sales 50% / net earnings 30% / gross margin 20%. CEO Rendle FY25 total comp ~$13.3M. (F)

Motivations of management? Operational stewards focused on margin recovery, productivity (ERP/IGNITE) and disciplined portfolio shaping; the EP metric suggests value-creation orientation. Combined Chair/CEO is a mild governance flag; first COO (Hyder) appointed June 2026. (I)

Valuation & Market Data

Is the stock an ADR, MLP, or K-1 issuer? No — a US C-corporation common stock (NYSE: CLX); standard 1099 dividend. (F)

Dividend policy? ~$4.96/year, ~5.1% yield, 47+ consecutive annual increases (Dividend Aristocrat); payout ~73% on normalized EPS. (F)

How profitable is the business? ~45% gross margin, ~16–17% operating margin, ~27% ROIC normalized — high-quality returns. (F)

Is net income diverging from cash from operations? Through the cycle, yes — GAAP net income was distorted by impairments and one-offs (FY23 NI only $149M on a $445M impairment), while OCF stayed in the $700M–1.3B range. Normalized, the two are converging (FY25 NI ~$810M, OCF $981M). Use normalized EPS / FCF, not trough GAAP. (F/I)

Risks & Downside

What factors would cause the stock to decline? Organic growth fading toward zero; gross-margin re-compression on an input-cost cycle; private-label breakthrough in bleach/Glad/litter; a GOJO integration stumble; another operational disruption (cyber/ERP); a dividend-coverage scare in a trough; further multiple de-rating on a terminal-decline narrative. (I)

Risk of a catastrophic loss? Very low — investment-grade, FCF-positive, #1/#2 share, 47-year dividend record. The realistic downside is a value trap (cheap stays cheap), not capital impairment. (I)

Chance of a total loss? Negligible. The negative book equity is a buyback artifact, not a solvency signal. (I)

Recent News & Events

Has the business environment changed recently? Yes — three notable shifts: (1) the July 2025 ERP go-live whipsawed reported sales and forced the H2 FY26 margin guide cut; (2) the GOJO/PURELL acquisition closed 1 April 2026; (3) a Middle East oil shock (~$100/bbl) emerged in Q4 FY26 as a ~130bps gross-margin headwind with FY27 annualization risk. (F)

Significant acquisitions? GOJO/PURELL (April 2026). (F)

Change in accounting policies? None material flagged; the new ERP is a systems change, not an accounting-policy change. (F)

Recent management/structural changes? Chris Hyder appointed first COO (17 June 2026); Linda Rendle combined Chair/CEO since January 2024; Luc Bellet CFO. Portfolio pruned (Argentina, vitamins); Glad JV bought in. (F)

APPENDIX B — Source Appendix

The Clorox Company (NYSE: CLX). Sources accessed 2026-06-27 unless noted. Primary sources first. Third-party aggregated data (ROIC.ai, AZI, FactorsToday) is reconciled to filings where it drives a verdict; the filing is authoritative.

Primary — SEC filings (EDGAR, CIK 0000021076)

1. Form 10-K, FY2025 (filed 2025-08-08; clx-20250630.htm + Ex-99.1 financial statements clx-20250630_d2.htm). Business description, four-segment net sales/EBIT, Walmart 27% customer concentration, product-line mix, raw materials, risk factors, organic-sales reconciliation, balance sheet, gross profit $3,213M / 45.2% margin.
2. Forms 10-K, FY2021–FY2024 (filed 2021-08-10, 2022-08-10, 2023-08-10, 2024-08-08). Multi-year segment, margin and balance-sheet history; impairments (FY23 $445M, FY21 $329M).
3. Form 10-Q, FY2026 Q1–Q3 (Sep-2025, Dec-2025, Mar-2026 periods). ERP destock, FY26 quarterly sales/margin, GOJO close.
4. DEF 14A proxy (filed 2025-10-07; e25287_clx-def14a.htm). Annual incentive metrics (net sales 50% / net earnings 30% / gross margin 20%); long-term PSUs on economic-profit growth; pay-versus-performance EP table; CEO Rendle FY25 total comp ~$13.33M; largest holders.
5. Form 4 corpus (145 filings since 2024-07-01). Insider transaction codes: P=3 (all director Pierre Breber: 2025-05-09 @ $136.57, 2025-11-24 @ $104.13, 2026-05-05 @ $85.82), S=9, A=50, F=73, M=3. No discretionary open-market selling by CEO/CFO.
6. 8-K material events: cyberattack disclosure (2023-08-14, Item 8.01); Better Health/VMS divestiture completed (2024-09-10, Item 7.01); GOJO acquisition agreement + $1.0B 364-day revolver (2026-03-10, Item 1.01); GOJO/PURELL close (1 April 2026); Chris Hyder appointed EVP & COO (2026-06-17, Item 5.02).

Primary — Earnings-call transcripts (via ROIC.ai)

7. FY2026 Q3 (2026-04-30) — the guidance cut: full-year gross-margin outlook cut from ~−100bps to −250/−300bps; oil shock (~$100/bbl ≈ $20–25M / ~130bps Q4); GOJO Q4 dilution; ERP declared complete.
8. FY2026 Q2 (2026-02-03) — sequential improvement; final ERP manufacturing phase live January; GOJO announced.
9. FY2026 Q1 (2025-11-03) — ERP destock; out-of-stocks/lost share; 7.5pt FY26 shipment headwind finalized.
10. FY2025 Q4 (2025-08-01) — original FY26 framework (ex-ERP: organic −1% to +2%, GM flat to +50bps, adj EPS +2–4%); CFO confirmation of the ~$7 normalized EPS bridge (+~$0.90 ERP add-back); ~18% EBIT-margin target.

Third-party — quantitative data (reconciled to filings)

11. ROIC.ai MCP — income statement, balance sheet, cash flow, profitability/valuation ratios (FY2016–FY2025 + TTM through Q3 FY26), enterprise value, per-share data. Note: ROIC’s FY2025 annual enterprise-value field ($2.87B) is a data error (missing market-cap component) and was discarded; real EV ≈ $14.1B.
12. AZI valuation index — own-history valuation percentiles (composite ~3rd; P/E 15.8x = 4th percentile; P/S 1.77x = 1.85th percentile; P/B null on negative book equity); price/OHLCV history CSV (split/dividend-adjusted; all-time nominal high ~$238 Aug-2020, decade low $86.12 on 2026-05-05).
13. FactorsToday — factor loadings (Consumer Staples ~0.73, Market ~0.45, BetaFactor −0.36/−0.64, DividendYield +0.21/+0.27, LowVolatility +0.19, Value +0.17, OilPrice −0.14/−0.18); leaderboard (beta 0.25; negative Sharpe at every horizon to 10y; 5-yr return −7.7%/yr; lifetime max drawdown −56%); related-stocks (KMB, XLP, VDC, MDLZ, PEP, KO, KHC) and idiosyncratic vol ~23%.
14. AZI news feed — recent items (thin; notable: COO appointment 2026-06-17). Validated against the underlying 8-K.

Peer comparison

15. Public peer disclosures and market data for Colgate-Palmolive (CL), Procter & Gamble (PG), Kimberly-Clark (KMB), Church & Dwight (CHD) and Unilever (UL) — used for industry structure, private-label data (~$282.8B / 21.3% dollar share, 2025), retailer-power framing, and peer multiples (CHD ~18x, CL/PG ~16x, KMB ~12x EV/EBITDA, with Clorox ~11x the cheap anchor).

Analytical frameworks

16. Competition Demystified (Greenwald & Kahn) — moat-type taxonomy, ROIC/market-share-stability tests applied in Sections 3–4. Capital Returns (Marathon) — supply-side capital-cycle analysis applied in Sections 3 and 7.